Authors

Jessica Bauman, MD, Fox Chase Cancer Center

Latest:

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.

Jessica Blackburn, PhD

Latest:

Zebrafish Are Making Waves as Cancer Models

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.

Jessica C. Gooch, MD

Latest:

Navigating the Job Search for Surgical Oncology Fellows

As the end of training approaches, the job hunt begins. Below are some tips to follow to make the job-hunting process easier.

Jessica DeMartino, PhD

Latest:

Impact of Risk Evaluation and Mitigation Strategies in Oncology

The management of risk in medicine is emerging as a priority topic for numerous stakeholders, including patients, providers (physicians, other prescribers, and pharmacists), specialty pharmacies, industry, and government organizations.

Jessica Donington, MD, MSCR

Latest:

How Biomarker Testing Could Continue to Evolve in NSCLC

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.

Jessica Frakes, MD

Latest:

Dr. Frakes on Late Toxicities in HPV-Associated Oropharynx Squamous Cell Carcinoma

Jessica Frakes, MD, assistant member, Department of Radiation Oncology, Moffitt Cancer Center, discusses some of the late toxicities seen in patients with HPV-positive oropharynx squamous cell carcinoma.

Jessica Geiger, MD

Latest:

Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial

Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma.

Jessica Hergert

Assistant Editor,

Latest:

Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in Myeloma

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

Jessica K. Altman, MD

Latest:

Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AML

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

Jessica K. Altman, MD, Northwestern University

Latest:

Emerging Combinations for FLT3-Mutated AML

Jessica K. Altman, MD, and Naval G. Daver, MD, review novel combinations under investigation for the treatment of FLT3-mutated acute myeloid leukemia.

Jessica Layne Berger, MD

Latest:

Dr. Berger on Chemotherapy Delivery Options in Ovarian Cancer

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Jessica Skarzynski

Latest:

Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPC

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

Jesus Berdeja, MD

Latest:

Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple Myeloma

Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.

Jesus G. Berdeja, MD

Latest:

Dr Berdeja on the Evolving Use of CAR T-Cell Therapy in Multiple Myeloma

Jesus Berdeja, MD, director, discusses the evolving guidelines regarding the use of CAR T-cell therapy in patients with multiple myeloma.

Jesus San Miguel, MD, PhD

Latest:

Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the ClÃnica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

Jia Ruan, MD, PhD

Latest:

Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Jian Li Campian, MD, PhD

Latest:

Enhancing Immune System May Boost Survival for Brain Cancer Patients

Researchers at Washington University in St. Louis and elsewhere are focusing on lymphocytes, the essential effector cells in the immune response to cancer.

Jianyu Rao, MD

Latest:

Dr. Rao on the Histogenesis of Endometrial Cancer

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses the histogenesis of endometrial cancer.

Jiaxin (Jason) Niu, MD, PhD

Latest:

Dr. Niu on Treatment Updates in RET+/KRAS+ NSCLC

Jason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.

Jihad Kaouk, MD

Latest:

Dr. Kaouk on Benefits of Robotic Partial Nephrectomy for RCC

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).